<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154488</url>
  </required_header>
  <id_info>
    <org_study_id>X4P-001-104</org_study_id>
    <nct_id>NCT04154488</nct_id>
  </id_info>
  <brief_title>A Study of Mavorixafor in Participants With Severe Congenital Neutropenia and Chronic Neutropenia Disorders</brief_title>
  <official_title>A Phase 1B, Open-Label, Multicenter Study of Mavorixafor in Patients With Severe Congenital Neutropenia and Chronic Neutropenia Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>X4 Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>X4 Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1b study will determine the safety and tolerability of mavorixafor in participants&#xD;
      with severe chronic idiopathic neutropenia (CIN) and selected congenital neutropenia&#xD;
      disorders. The anticipated enrollment is up to 25 participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">July 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline (Day -1) up to end of study (Day 44)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to 8 hours post-dose in Absolute Neutrophil Count (ANC) of Mavorixafor</measure>
    <time_frame>Time 0 (pre-dose, up to 15 minutes prior), 60 minutes (each ± 5 minutes) and 2, 3, 4, 6, and 8 hours (each ± 15 minutes) post-dose at Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for ANC (AUCANC) of Mavorixafor</measure>
    <time_frame>Time 0 (pre-dose, up to 15 minutes prior), 60 minutes (each ± 5 minutes) and 2, 3, 4, 6, and 8 hours (each ± 15 minutes) post-dose at Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Mavorixafor in Relation to ANC and AUCANC</measure>
    <time_frame>Time 0 (pre-dose, up to 15 minutes prior), 60 minutes (each ± 5 minutes) and 2, 3, 4, 6, and 8 hours (each ± 15 minutes) post-dose at Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>Mavorixafor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult participants and adolescent participants who weigh more than 50 kilograms (kg) will receive mavorixafor 400 milligrams (mg) (4 capsules of 100 mg each) once on Day 1. Adolescents weighing less than or equal to 50 kg will receive mavorixafor 200 mg (2 capsules of 100 mg each) once on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mavorixafor</intervention_name>
    <description>Mavorixafor capsules will be administered per dose and schedule specified in the arm.</description>
    <arm_group_label>Mavorixafor</arm_group_label>
    <other_name>X4P-001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  For all participants:&#xD;
&#xD;
               -  Sign the informed consent form (ICF) and be willing and able to comply with the&#xD;
                  protocol.&#xD;
&#xD;
               -  Weigh ≥15 kg&#xD;
&#xD;
               -  Agree to use contraception as follows:&#xD;
&#xD;
                  i) Women of childbearing potential (WOCBP): agree to use a highly-effective form&#xD;
                  of contraception.&#xD;
&#xD;
               -  Participants who are on granulocyte-colony stimulating factor (G-CSF) must be on&#xD;
                  a stable dose for at least 14 days prior to enrollment and for the duration of&#xD;
                  the study.&#xD;
&#xD;
               -  Participants who are not on G-CSF must be off for at least 14 days prior to&#xD;
                  enrollment and for the duration of the study.&#xD;
&#xD;
               -  Have an absolute neutrophil count (ANC) &lt; 1000 cells/µL at the screening and&#xD;
                  baseline visits.&#xD;
&#xD;
               -  Participants on G-CSF are allowed if their screening and baseline ANC is ≥1000&#xD;
                  cells/uL. Participants with cyclical neutropenia are required to have ANC &lt;1000&#xD;
                  cells/ µL only at the baseline visit&#xD;
&#xD;
               -  Have been diagnosed chronic neutropenia for at least 6 months prior to screening&#xD;
                  that is not attributable to medications, active or recent (within 3 months)&#xD;
                  infections, or malignant cause.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Known systemic hypersensitivity to the mavorixafor drug substance or its inactive&#xD;
             ingredients.&#xD;
&#xD;
          -  Is pregnant or nursing.&#xD;
&#xD;
          -  Known history of a positive serology or viral load for human immunodeficiency virus&#xD;
             (HIV) or a known history of acquired immune deficiency syndrome.&#xD;
&#xD;
          -  At screening, has laboratory test results meeting one or more of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Positive hepatitis C virus (HCV) antibodies with confirmation by HCV-ribonucleic&#xD;
                  acid polymerase chain reaction reflex testing.&#xD;
&#xD;
               -  Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody&#xD;
                  (HBcAb).&#xD;
&#xD;
        Note: If a participant tests negative for HBsAg but positive for HBcAb, the participant&#xD;
        would be considered eligible if the participant tests positive for antibody to HBsAg reflex&#xD;
        testing.&#xD;
&#xD;
          -  At screening, has laboratory test results meeting one or more of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Hemoglobin &lt;9.0 grams/deciliter (g/dL)&#xD;
&#xD;
               -  Platelet count &lt;30,000/μL&#xD;
&#xD;
               -  Mild/moderate renal impairment 30 to 60 glomerular filtration rate&#xD;
&#xD;
               -  Serum aspartate transaminase &gt;2.5 * upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum alanine transaminase &gt;2.5 * ULN&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 * ULN (unless due to Gilbert's syndrome, in which case total&#xD;
                  bilirubin greater than or equal to (≥) 3.0 * ULN and direct bilirubin &gt;1.5 * ULN)&#xD;
&#xD;
          -  Within 2 weeks before Day 1, received any of the following treatments:&#xD;
&#xD;
               -  Glucocorticoids (&gt;5 mg prednisone equivalent per day)&#xD;
&#xD;
               -  Medication prohibited based on cytochrome P450 (CYP) and/or transporter-based&#xD;
                  (such as, P-glycoprotein ([P-gp]) potential for drug-drug interaction.&#xD;
&#xD;
          -  At the planned initiation of study drug, has an infection requiring use of antibiotics&#xD;
             (systemic or inhaled) or took systemic antibiotics within 4 weeks before Day 1.&#xD;
&#xD;
          -  Has any other medical or personal condition that, in the opinion of the Investigator,&#xD;
             may potentially compromise the safety or compliance of the participant, or may&#xD;
             preclude the participant's successful completion of the clinical study.&#xD;
&#xD;
          -  Inability to ingest capsules of study drug as presented.&#xD;
&#xD;
          -  Has a history of any hematologic malignancy.&#xD;
&#xD;
          -  Diagnosed or have congenital long QT syndrome. Any history of clinically significant&#xD;
             ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or&#xD;
             torsades de pointes); any history of arrhythmia will be discussed with the sponsor's&#xD;
             medical monitor before participant's entry into the study.&#xD;
&#xD;
          -  Prolonged corrected QT interval (QTc) using Fridericia's formula (QTcF) on pre-entry&#xD;
             electrocardiogram (ECG) (≥450 milliseconds [ms]).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patient Affairs and Advocacy</last_name>
    <phone>857-529-5779</phone>
    <email>clinicaltrialinfo@x4pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Iowa Hospital and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjali Sharathkumar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jo Walkovich</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Wilson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Feinstein Institutes for Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrianna Vlachos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seth Corey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David C. Dale</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic congenital neutropenia</keyword>
  <keyword>Chronic idiopathic neutropenia</keyword>
  <keyword>SCN</keyword>
  <keyword>CIN</keyword>
  <keyword>CXCR4</keyword>
  <keyword>Mavorixafor</keyword>
  <keyword>Neutropenia glycogen storage disease type 1b</keyword>
  <keyword>GSD1b</keyword>
  <keyword>G6PC3</keyword>
  <keyword>SLC37A4</keyword>
  <keyword>GATA2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

